EGFR and glioblastoma: Although EGFRvIII [73] and deletions in the C-terminal domain (Δ25-27/28) were shown to sensitize GBM cells to Erlotinib [25], none of the EGFR structural variants present in our testing group systematically sensitized tumors to any of the EGFR inhibitors.